Shanghai, China

Yongfeng Sun

USPTO Granted Patents = 6 


 

Average Co-Inventor Count = 15.3

ph-index = 2

Forward Citations = 17(Granted Patents)


Company Filing History:


Years Active: 2017-2024

where 'Filed Patents' based on already Granted Patents

6 patents (USPTO):

Title: The Innovations of Yongfeng Sun: Pioneering Triazolopyrimidine Compounds

Introduction: Yongfeng Sun, an accomplished inventor based in Shanghai, China, has made significant contributions to the field of pharmaceutical science. With a total of six patents to his name, he is recognized for his innovative work on novel compounds that have the potential to address serious medical conditions.

Latest Patents: Yongfeng's most recent patents include groundbreaking work on Triazolopyrimidine compounds. These compounds are characterized by a specific formula, which has been shown to be effective in treating diseases associated with PRC2 (Polycomb Repressive Complex 2)-mediated disorders. The details of these compounds underscore their importance in the pharmaceutical landscape, providing new avenues for therapeutic development.

Career Highlights: As a vital member of Novartis AG, Yongfeng Sun demonstrates exceptional ingenuity and dedication to advancing medical research. His relentless pursuit of innovation in drug development plays a crucial role in shaping the future of treatments for complex diseases.

Collaborations: Throughout his career, Yongfeng has worked alongside distinguished colleagues, including Ho Man Chan and Xiang-Ju Justin Gu. These collaborations have fostered a creative environment that has led to the successful development of several patented innovations.

Conclusion: Yongfeng Sun is a significant figure in the field of pharmaceuticals, renowned for his inventive contributions and practical applications of Triazolopyrimidine compounds. His work at Novartis AG and collaboration with talented professionals continue to drive advancements in medical science, paving the way for new therapies and solutions to challenging health issues.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…